| Година | Наслов | Аутор(и) | Тип резултата | Мп-кат. |
| 2021 | IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2021 | Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C | Dziadziuszko, R; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Научни чланак | 21a+M21a+ - Водећи међународни часопис категорије M21a+ |
| 2021 | A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction. | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zoran; ...; (broj, koautora 17) | Конференцијски рад | |
| 2021 | First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) | Andric, Zoran G ; ...; Stojanovic, Goran; Petrovic, Marina D ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2021 | 565Tip A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2-breast cancer | Abramson, V; ...; Andric, Zoran G ; Milovic-Kovacevic, Marijana M ; Trifunovic, Jasna D; ...; (broj, koautora 16) | Конференцијски рад | |
| 2021 | Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2). | Goel, Shom; O'Shaughnessy, Joyce; Tan, Antoinette R; Milev-Krastev, Boris; Rugo, Hope S; Aftimos, Philippe Georges; Yardley, Denise A; Andric, Zoran G ; Wolfgang, Curt Douglas; Sorrentino, Jessica;
Tao, Wenli; Beelen, Andrew Paul; Malik, Rajesh K; Jain, Sarika;
| Конференцијски рад | |
| 2021 | HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j | Laeufle, Rita; ...; Andric, Zoran G ; ...; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z; ...; (broj, koautora 16) | Конференцијски рад | |
| 2021 | Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) | Trukhin, Dmytro; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Научни чланак | 21aM21a - Водећи међународни часопис категорије M21a |
| 2020 | Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2020 | Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study. | Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, Cristina | Конференцијски рад | |
| 2020 | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial | Mansfield, AS; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Научни чланак | 21a+M21a+ - Водећи међународни часопис категорије M21a+ |
| 2020 | Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924 | Andric, Zoran G ; Ceric, Timur; Stanetic, Mirko; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Smit, E; Ulanska, M; Caldwell, C;
Ferrari, D; Annis, A; Vukovic, V; Zaric, Bojan  ;
| Конференцијски рад | |
| 2020 | Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. | Jared, Weiss; Jerome, Goldschmidt; Andric, Zoran G ; Konstantin, Dragnev H; Yili, Pritchett; Shannon, Morris R; Rajesh, Malik K; Davey, Daniel B | Конференцијски рад | |
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 22) | Научни чланак | 21a+M21a+ - Водећи међународни часопис категорије M21a+ |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Конференцијски рад | |
| 2020 | Hypertension in Polycystic Ovary Syndrome: Novel Insights | Macut, Đuro ; Mladenović, Violeta ; Bjekić-Macut, Jelica ; Livadas, Sarantis; Stanojlović, Olivera ; Hrnčić, Dragan ; Rašić-Marković, Aleksandra ; Vojnović-Milutinović, Danijela ; Andrić, Zoran  | Научни чланак | 23M23 - Међународни часопис категорије M23 |
| 2020 | Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, PlaceboControlled Phase II Study | Hart Lowel L; Ferrarotto Renata; Andrić Zoran G ; Beck Thaddeus J; Subramanian Janakiraman; Radosavljević Davorin Z ; Zarić Bojan ; Hanna Wahid T; Aljumaily Raid; Owonikoko Taofeek K;
Verhoeven Didier; Xiao Jie; Morris Shannon R; Antal Joyce M; Hussein Maen A;
| Научни чланак | 21M21 - Водећи међународни часопис категорије M21 |
| 2020 | Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC | Reinmuth, Niels; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2019 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Конференцијски рад | |